Description
While studies suggest modulating IGF pathways may ameliorate AD pathology, the authors explicitly note that safety and efficacy of IGF-based treatments remain unevaluated. This knowledge gap is essential for clinical translation.
Gap type: open_question Source paper: Insulin-Like Growth Factor Signaling in Alzheimer’s Disease: Pathophysiology and Therapeutic Strategies. (2025, Molecular neurobiology, PMID:39240280)
Resolution criteria
[“Randomized controlled phase I/II trial (n>=80 AD patients) of IGF-1 or IGF-1R agonist shows >=30% slower decline on ADAS-Cog13 vs placebo over 12 months”, “CSF biomarkers (A\u03b242, t-tau, p-tau181) show significant modulation from baseline in treatment arm”, “Safety monitoring (MRI for microhemorrhages, fasting glucose) across all participants confirms tolerability”, “Dose-response analysis establishes therapeutic window between efficacy and adverse effects (edema, hypoglycemia)”]
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:16.528020+00:00”, “resolution_summary”: “Resolved by hypothesis h-a1b56d74: Metabolic Switch Targeting for A1→A2 Repolarization. Supporting evidence includes debate sess_SDA-2026-04-08-gap-pubmed-20260406-062212-6777e5dd_task_9aae8fc5.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-a1b56d74”, “title”: “Metabolic Switch Targeting for A1→A2 Repolarization”, “score”: 0.224, “reason”: “21 token overlaps; entity overlap: igf”, “analysis_id”: “sda-2026-04-01-gap-007”, “target_gene”: “HK2”, “target_pathway”: “Insulin/IGF metabolic signaling”, “disease”: “neurodegeneration”, “composite_score”: 0.726066, “confidence_score”: 0.55, “status”: “debated”, “pubmed_evidence_ids”: [“26075878”, “26975021”, “33946854”, “38904014”, “40014451”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062212-6777e5dd_task_9aae8fc5”, “title”: “While ALS-causing mutations impair autophagy factors, the neuron-specific effects remain incompletely defined according to the authors. This knowledge gap prevents precise understanding of selective neuronal vulnerability in ALS.\n\nGap type: open_question\nSource paper: Autophagy and ALS: mechanistic insights and therapeutic implications. (2022, Autophagy, PMID:34057020)”, “score”: 0.424, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062212-6777e5dd”, “quality_score”: 0.812, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-16-gap-pubmed-20260410-145418-c1527e7b”, “title”: “There’s a clear disconnect between improved mechanistic understanding of AD and therapeutic success, with continued phase 3 trial failures. This translation gap suggests fundamental flaws in target selection, trial design, or disease model assumptions that need resolution.\n\nGap type: contradiction\nSource paper: Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. (2019, Cell, PMID:31564456)”, “score”: 0.419, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-16-gap-pubmed-20260410-145418-c1527e7b”, “quality_score”: 0.5, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1_task_9aae8fc5”, “title”: “The abstract identifies APOE4 association with increased TDP-43 pathology but the mechanistic link is unexplained. This connection could reveal novel therapeutic targets since APOE4 is the strongest genetic risk factor for AD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.403, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1”, “quality_score”: 0.61, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a_task_9aae8fc5”, “title”: “AD patients with TDP-43 pathology show worse cognitive impairment, but how TDP-43 mechanistically contributes to this severity is unknown. Understanding this could identify TDP-43 as a therapeutic target for cognitive preservation in AD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.398, “reason”: “8 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a”, “quality_score”: 0.734, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-12-gap-pubmed-20260410-180503-a7a03974_20260412-213444”, “title”: “The abstract suggests that Aβ-tau synergy could explain negative results from anti-Aβ trials, contradicting the expectation that targeting the presumed initiating pathology would be therapeutic. This contradiction has major implications for therapeutic strategy design.\n\nGap type: contradiction\nSource paper: Synergy between amyloid-β and tau in Alzheimer’s disease. (2020, Nature neuroscience, PMID:32778792)”, “score”: 0.394, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-12-gap-pubmed-20260410-180503-a7a03974”, “quality_score”: 0.7, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}